Related Experiment Video
Updated: Jun 7, 2026
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
The complete preventive effect of homologous tumor vaccines--based on a 5-year experimental study in mice
Xinglong Tong1, Ling Wang, Yanping Liu
1Hebei Xinglong medical and pharmaceutical institute, 232 South Zhonghua Street, Shijiazhuang 050056, PR China. xinglongtong@hotmail.com
Abstract:
By using a frozen-thaw method, we developed homologous and heterologous cell-based tumor vaccines, which were derived from mouse H22 hepatoma, S180 sarcoma and human A549 lung carcinoma, SK-OV-3 ovarian, and SMMC-7721 hepatoma cell lines. The prophylactic and therapeutic effects of those vaccines were evaluated in mice challenged with live H22 or S180 cells. The result demonstrated that homologous vaccines and heterologous vaccines had no therapeutic effect on tumor growth. However, homologous vaccines showed a complete prevention against live H22 and S180 cell challenge and they could stimulate cross-immune response of anti-tumor in mice. Furthermore, these tumor-free mice immunized with homologous vaccines showed full protection against the repeat challenge every 3 months for 5 years. The study also revealed that tumor-free female, not male, mice transferred anti-tumor ability to some of their offsprings. Heterologous vaccines exhibited no protective effect on tumor development. Immunological analysis discovered that activities of CTLs and NK were enhanced and the levels of IL-2, IL-12 and IFN-γ were significantly increased. Our results demonstrated that homologous tumor vaccines could elicit complete cross-protection against the lethal challenge of tumor cells through enhancing cell-mediated immune response, which lasted for 5 years in mice. These observations may provide a new vaccine strategy for tumor prevention.
Insights
Homologous tumor vaccines prevent cancer in mice by boosting cell-mediated immunity. This cross-protection lasts for five years, offering a novel vaccine strategy for tumor prevention.
Area of Science:
- Immunology
- Oncology
- Vaccinology
Background:
- Cell-based tumor vaccines are being explored for cancer prevention and treatment.
- Developing effective tumor vaccines requires understanding immune responses and long-term protection.
Purpose of the Study:
- To develop and evaluate homologous and heterologous cell-based tumor vaccines.
- To assess the prophylactic and therapeutic effects of these vaccines in mice.
- To investigate the long-term protective immunity and underlying immunological mechanisms.
Main Methods:
- Frozen-thaw method used to create homologous and heterologous cell-based tumor vaccines from mouse and human cell lines.
- Vaccine efficacy tested in mice challenged with live tumor cells (H22 hepatoma, S180 sarcoma).
- Immunological analyses included assessing cytotoxic T lymphocyte (CTL) and Natural Killer (NK) cell activity, and cytokine levels (IL-2, IL-12, IFN-γ).
Main Results:
- Homologous vaccines provided complete protection against tumor cell challenge and induced long-term (5-year) cross-protection.
- Heterologous vaccines showed no therapeutic or prophylactic effect.
- Enhanced CTL and NK cell activities, along with increased IL-2, IL-12, and IFN-γ levels, were observed.
- Tumor-free female mice, but not males, could transfer anti-tumor immunity to offspring.
Conclusions:
- Homologous cell-based tumor vaccines can induce complete and long-lasting cross-protective immunity against lethal tumor cell challenge.
- The protective effect is mediated by enhanced cell-mediated immune responses.
- This approach presents a promising new vaccine strategy for tumor prevention.
Related Concept Videos
02:43Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...